Virbac confirms outlook as Supercharge platforms drive profit growth

By Reuters News

Sept 17 (Reuters) - French animal health company Virbac VIRB.PA reported higher half-year core profit on Thursday with a recurring operating profit, excluding amortization of assets due to acquisitions, rising 6.8% to 144.2 million euros ($165.50 million), compared with 135.0 million euros a year earlier.

Virbac confirmed its 2026 outlook at the upper end of its target range (5.5%-7.5%), with CEO Paul Martingell citing the "scaling power" of the group's Supercharge platforms and the successful integration of Thyronorm.

  • Revenue reached 768 million euros, up 7.4% at constant exchange rates and scope, driven by companion animal growth of 10.0% and farm animal growth of 6.7%.

  • "This performance reflects the scaling power of our 'Supercharge' platforms" said CEO Paul Martingell.

  • Virbac said its "Supercharge" platforms grew about 12% excluding Thyronorm, while the acquisition contributed an additional 3.7 percentage points to platform growth and strengthened its endocrinology business.

  • Virbac acquired feline hyperthyroidism drug Thyronorm, sold as Felanorm in the US, from Norbrook in December 2025.

  • The company also highlighted two specialty-asset deals, Porus-One and Vetcare, as part of its strategy to add high-margin complementary products.

($1 = 0.8713 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.